Elicio Therapeutics, Inc. ELTX
1.84
(0.04)
(2.13%)
as of 25 Sep
- Market cap
- $53.4M
- P/E
- 0.0×
Follow ELTX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
P/S ratio |
— | — | — | 0.10 | 2.89 | 89.87 | 89.87 | 89.87 | — |
P/FCF ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
P/Operating CF |
— | — | — | (0.38) | (5.70) | 12.57 | 12.57 | 12.57 | — |
P/B ratio |
— | — | — | 0.00 | 1.01 | 0.00 | 0.00 | 0.00 | — |
Price to Tangible BV |
— | — | — | 0.00 | 1.01 | 0.00 | 0.00 | 0.00 | — |
EV/Sales |
— | — | — | (0.05) | (0.20) | 78.16 | 78.16 | 78.16 | — |
EV/EBITDA |
— | — | — | 0.06 | 0.16 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
— | — | — | 0.06 | 0.11 | (9.84) | (9.84) | (9.84) | — |
EV/FCF |
— | — | — | 0.06 | 0.11 | (9.82) | (9.82) | (9.82) | — |
Quick Ratio |
2.29 | 1.63 | 1.40 | 1.18 | 7.93 | 0.32 | 0.23 | 3.48 | — |
Current Ratio |
2.38 | 1.80 | 1.68 | 1.56 | 8.08 | 0.39 | 0.23 | 3.49 | — |
Net Debt/EBITDA |
0.25 | (0.03) | 0.39 | 0.29 | 2.39 | 0.72 | (0.14) | 1.78 | — |
Debt/Assets |
36.37% | 71.10% | 0.00% | 5.42% | 1.17% | 1.89% | 90.68% | 0.00% | 0.00% |
Debt/Equity |
5.75 | (1.77) | 0.00 | 0.14 | 0.01 | (0.01) | (0.58) | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.04 | 0.39 | 0.10 | 0.08 | 0.30 | — |
Operating CF/Net income |
0.93 | 0.71 | 0.93 | 0.79 | 0.96 | 0.29 | 0.60 | 0.32 | — |
Capex/Depreciation |
(0.01) | (0.07) | (0.03) | (0.62) | (0.14) | 0.00 | (0.49) | 0.00 | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| 817.92% | (170,157.38%) | 77.55% | 273.36% | 1,220.60% | 146.94% | (25,020.31%) | (15,387.69%) | — | |
| (146.45%) | (187.61%) | (141.32%) | (47.34%) | (75.87%) | (270.48%) | (211.13%) | (187.81%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | (632.00%) | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(344.22%) | (537.64%) | (481.46%) | (564.61%) | (67.88%) | 123.25% | 200.68% | (136.33%) | — |
Average Days of Receivables |
— | — | — | 48.38 | 10.39 | 0.00 | 108.00 | 9.69 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 786.74% | 172.00% | 1,353.37% | 2,006.52% | 312.78% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 244.68% | 65.30% | 624.51% | 645.66% | 133.80% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 25.16% | 42.53% | 163.75% | 224.34% | 0.00% | — |
Graham Net Nets |
— | — | — | (1.10) | 0.93 | (0.37) | (0.37) | (0.37) | — |
Graham Number |
— | — | — | 619.14 | 0.00 | 268.96 | 0.00 | 0.00 | — |
Earnings Yield |
— | — | — | (604.43%) | (72.07%) | (31.76%) | (31.76%) | (31.76%) | — |
Free Cash Flow Yield |
— | — | — | (829.93%) | (64.74%) | (8.86%) | (8.86%) | (8.86%) | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 7.28 | 10.02 | 1.95 | 1.03 | 1.37 | — |
Operating CF per Share |
(2.41) | (3.04) | (6.47) | (70.19) | (18.64) | (15.50) | (17.03) | (2.72) | — |
Capex per Share |
0.00 | (0.01) | (0.01) | (2.07) | (0.14) | (0.03) | (0.17) | 0.00 | — |
Free Cash Flow per Share |
(2.41) | (3.04) | (6.47) | (72.26) | (18.77) | (15.53) | (17.20) | (2.72) | — |
Cash per Share |
1.21 | 1.54 | 2.69 | 24.67 | 31.42 | 23.44 | 3.86 | 8.66 | — |
Shareholders Equity per Share |
0.11 | (0.93) | 2.25 | 28.21 | 28.86 | (61.27) | (12.88) | 6.42 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.11 | (0.93) | 2.25 | 28.21 | 28.86 | (61.27) | (12.88) | 6.42 | — |
Free Cash Flow |
(36.97) | (37.15) | (32.73) | (22.83) | (53.02) | (22.93) | (24.83) | (8.02) | — |
Working Capital |
11.20 | 9.17 | 6.59 | 3.85 | 79.95 | (65.15) | (20.47) | 18.32 | — |
Capital Expenditures |
(0.02) | (0.08) | (0.03) | (0.65) | (0.38) | (0.04) | (0.24) | — | — |
Net Current Asset Value |
(4.91) | (18.80) | 0.58 | (3.03) | 76.24 | (95.50) | (24.37) | 17.96 | — |
EV/EBIT |
— | — | — | 0.06 | 0.15 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.28 | 0.01 | 0.01 | 0.16 | 0.00 | — |
Net Profit Margin |
0.00% | 0.00% | 0.00% | (1,225.90%) | (192.76%) | (2,781.49%) | (2,734.23%) | (620.63%) | — |
Price to Operating Income |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
4.56 | 2.59 | 1.63 | 0.92 | 5.95 | 53.13 | 2.37 | 0.12 | — |
Cash ROIC |
(125.81%) | (136.46%) | (133.70%) | (130.02%) | (30.98%) | 41.94% | 1,108.54% | (18.09%) | — |
Accounts Receivable Turnover |
— | — | — | 4.14 | 45.44 | 0.00 | 5.44 | 14.73 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.26 | 0.08 | 0.14 | 0.11 | 0.06 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 1,033.12 | 3,970.32 | 1,710.90 | 6,409.74 | 515.63 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
— | — | — | 0.56 | 0.62 | — | 0.27 | 0.27 | — |
Average Payables |
0.86 | 2.70 | 3.59 | 3.76 | 5.14 | 8.41 | 5.89 | 5.89 | — |
Average Assets |
27.02 | 27.66 | 24.91 | 59.59 | 71.93 | 29.62 | 19.26 | 13.31 | — |
Average Common Equity |
(4.84) | 0.03 | (45.39) | (10.32) | (4.47) | (54.52) | 0.16 | 0.16 | — |
Columns are period end dates